NCT07680842 Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
| NCT ID | NCT07680842 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Drug-Resistant Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-09 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-09 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy. LIFU uses focused sound waves to modulate deep brain regions and to enable changes in brain network activity. Encephalography (EEG) and behavioral tasks will also be used to study how LIFU affects brain activity.
Eligibility Criteria
Inclusion Criteria * Male or female between 21 and 65 years of age at screening * Clinical diagnosis of drug-resistant epilepsy with on average, 4 or more seizures per month. * Able to provide informed consent (or assent when applicable) by the subject or subject's legal representative. * Be willing to undergo a brain MRI. * Be able and willing to wear a headband during the treatment duration. * Be able to complete scheduled visits and daily seizure logs. Exclusion Criteria * Has a craniotomy or pathologic intracranial lesion (e.g. vascular malformations) in the trajectory of the focused ultrasound beam. * Pregnant, breastfeeding, is attempting pregnancy, or unwilling to practice birth control during participation in the study. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Has any unstable medical or psychiatric disease. * Any contraindications for completing a brain MRI scan. * Has evidence of any other clinically relevant neurological disorder at the time of screening, including Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
Contact & Investigator
Joline M Fan, MD, MS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07680842 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Drug-Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07680842 currently recruiting?
Yes, NCT07680842 is actively recruiting participants. Contact the research team at lifu.research@ucsf.edu for enrollment information.
Where is the NCT07680842 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07680842 clinical trial?
NCT07680842 is sponsored by University of California, San Francisco. The principal investigator is Joline M Fan, MD, MS at University of California, San Francisco. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.